Latest Clinical Trials
The Canadian Organization for Rare Disorders advocates for better diagnosis and drug access for Canada’s 3 million people with rare diseases.
Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease of the central nervous system (CNS). It is also characterized by inflammation and axonal degeneration in the CNS and is vastly heterogeneous in its presentation.1 Diagnosis of MS has improved over time; however, there is still room for improvement: the mean time from first medical…
CAESAREA, Israel — Multiple sclerosis survivor Michael Faibisch, 59, clearly remembers the day in August 2003 when his symptoms began. The Maryland native, who’s lived in Israel since 1979, had started long-distance bicycling a year earlier to get back in shape. At the time, he weighed 130 kilograms (287 pounds) and was an emotional wreck. “I…
Growing old with multiple sclerosis (MS) comes with its own complications. A disease on top of the normal aging process adds another layer of difficulty.
Multiple sclerosis (MS) is a disease of progression. Because of its unique properties, there is no set pattern.
Multiple sclerosis (MS) symptoms are a mystery for most of us living with this chronic illness.
MS Clinical Insights
We explore the role of ASOs in MS treatment today, and why combination therapy may produce better clinical outcomes.
In the management of any disease in which relapses are known to occur, it is important to identify the risk factors for their occurrence, as well as any other factors that might influence their severity. In this article, we will be assessing the risk factors for relapse in patients with neuromyelitis optica spectrum disorder (NMOSD)…
We examine how hypoxia drives inflammation in multiple sclerosis—and how the opposite can happen as well.
The blood-brain barrier is the guardian of the central nervous system, but its stubborn resistance to DMTs presents a unique problem to medical researchers.